Macrophage renewal modes affect acquired resistance to gefitinib in EGFR‑mutant lung cancer PC‑9 cells

Zhao,Baoxia; Zhao,Baoxia; Zhang,Yan; Zhang,Yan; Lu,Shen; Lu,Shen; Li,Mei; Li,Mei

doi:10.3892/or.2022.8467

Macrophage renewal modes affect acquired resistance to gefitinib in EGFR‑mutant lung cancer PC‑9 cells

Authors:
- Baoxia Zhao
- Yan Zhang
- Shen Lu
- Mei Li
View Affiliations

Affiliations: Scientific Research Center, The Second Hospital of Dalian Medical University, Dalian, Liaoning 116027, P.R. China
Published online on: December 21, 2022 https://doi.org/10.3892/or.2022.8467
Article Number: 30

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

EGFR tyrosine kinase inhibitors (TKIs) have been successfully used in lung cancer treatment. Nevertheless, tumor cells may develop resistant phenotypes in the tumor microenvironment after a period of treatment with any generation of EGFR TKIs. Macrophages play a pivotal role in carcinogenesis and development. At the same time, macrophages renew continuously, and their polarized phenotype changes dynamically. Although macrophage polarization is generally considered to be involved in secondary resistance, it would be time consuming if renewed macrophages would only protect tumor cells from drug attacks after polarization. It is unclear how dynamic renewal of macrophage contributes to acquired resistance. By using two co‑culture approaches, the present study modeled two types of renewal of macrophages: Migrated macrophages (Mm) and locally self‑renewal resident macrophages (Mr). The EGFR‑mutant lung cancer cell line PC‑9 was induced to develop resistance to gefitinib in these co‑culture approaches and without macrophages co‑culture. PC‑9 cells induced in Mm co‑culture recovered fast from gefitinib attack, and formed the gefitinib resistant (GR) subline PC‑9/Mm/GR with the strongest resistant ability. PC‑9/Mm/GR cells exhibited epithelial characteristics, including stable expression of EGFR, phosphorylated EGFR, insulin‑like growth factor 1 receptor, TGF‑βII receptor and E‑cadherin. PC‑9 cells induced in Mr co‑culture and those without co‑culture developed similar weak resistance to gefitinib. TGF‑β secretion was inhibited when PC‑9 cells were in Mr co‑culture, but not in Mm co‑culture. Macrophages were not polarized in either co‑culture type. The present findings suggested that macrophages may affect resistance acquirement by different renewal modes. Mm could promote resistance acquirement by stabilizing tumor cell phenotypes, which would happen before polarization. It would be helpful to monitor the response to EGFR‑TKIs and design novel treatment strategies if macrophages from two renewal modes were distinguished effectively.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
2	Ohashi K, Maruvka YE, Michor F and Pao W: Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol. 31:1070–1080. 2013. View Article : Google Scholar : PubMed/NCBI
3	Konig D, Prince SS and Rothschild SI: Targeted therapy in advanced and metastatic non-small cell lung cancer. An update on treatment of the most important actionable oncogenic driver alterations. Cancers (Basel). 13:804–840. 2021. View Article : Google Scholar : PubMed/NCBI
4	Bivona TG and Doebele RC: A framework for understanding and targeting residual disease in oncogene-driven solid cancers. Nat Med. 22:472–478. 2016. View Article : Google Scholar : PubMed/NCBI
5	Lin A, Wei T, Meng H, Luo P and Zhang J: Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. Mol Cancer. 18:1392019. View Article : Google Scholar : PubMed/NCBI
6	Loyher PL, Hamon P, Laviron M, Meghraoui-Kheddar A, Goncalves E, Deng Z, Torstensson S, Bercovici N, de Chanville CB, Combadière B, et al: Macrophages of distinct origins contribute to tumor development in the lung. J Exp Med. 215:2536–2553. 2018. View Article : Google Scholar : PubMed/NCBI
7	Bonde AK, Tischler V, Kumar S, Soltermann A and Schwendener RA: Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors. BMC Cancer. 12:352012. View Article : Google Scholar : PubMed/NCBI
8	Mantovani A, Marchesi F, Malesci A, Laghi L and Allavena P: Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 14:399–416. 2017. View Article : Google Scholar : PubMed/NCBI
9	De Palma M and Lewis CE: Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell. 23:277–286. 2013. View Article : Google Scholar : PubMed/NCBI
10	Mantovani A and Allavena P: The interaction of anticancer therapies with tumor-associated macrophages. J Exp Med. 212:435–445. 2015. View Article : Google Scholar : PubMed/NCBI
11	Jia Y, Li X, Jiang T, Zhao S, Zhao C, Zhang L, Liu X, Shi J, Qiao M, Luo J, et al: EGFR-targeted therapy alters the tumor microenvironment in EGFR-driven lung tumors: Implications for combination therapies. Int J Cancer. 145:1432–1444. 2019. View Article : Google Scholar : PubMed/NCBI
12	Wang DH, Lee HS, Yoon D, Berry G, Wheeler TM, Sugarbaker DJ, Kheradmand F, Engleman E and Burt BM: Progression of EGFR-mutant lung adenocarcinoma is driven by alveolar macrophages. Clin Cancer Res. 23:778–788. 2017. View Article : Google Scholar : PubMed/NCBI
13	Garrido-Martin EM, Mellows TWP, Clarke J, Ganesan AP, Wood O, Cazaly A, Seumois G, Chee SJ, Alzetani A, King EV, et al: M1(hot) tumor-associated macrophages boost tissue-resident memory T cells infiltration and survival in human lung cancer. J Immunother Cancer. 8:e0007782020. View Article : Google Scholar : PubMed/NCBI
14	Xiao F, Liu N, Ma X, Qin J, Liu Y and Wang X: M2 macrophages reduce the effect of gefitinib by activating AKT/mTOR in gefitinib-resistant cell lines HCC827/GR. Thorac Cancer. 11:3289–3298. 2020. View Article : Google Scholar : PubMed/NCBI
15	Zhang B, Zhang Y, Zhao J, Wang Z, Wu T, Ou W, Wang J, Yang B, Zhao Y, Rao Z and Gao J: M2-polarized macrophages contribute to the decreased sensitivity of EGFR-TKIs treatment in patients with advanced lung adenocarcinoma. Med Oncol. 31:1272014. View Article : Google Scholar : PubMed/NCBI
16	Chung FT, Lee KY, Wang CW, Heh CC, Chan YF, Chen HW, Kuo CH, Feng PH, Lin TY, Wang CH, et al: Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer. Int J Cancer. 131:E227–E235. 2012. View Article : Google Scholar : PubMed/NCBI
17	Gentek R, Molawi K and Sieweke MH: Tissue macrophage identity and self-renewal. Immunol Rev. 262:56–73. 2014. View Article : Google Scholar : PubMed/NCBI
18	Mascia F, Lam G, Keith C, Garber C, Steinberg SM, Kohn E and Yuspa SH: Genetic ablation of epidermal EGFR reveals the dynamic origin of adverse effects of anti-EGFR therapy. Sci Transl Med. 5:199ra1102013. View Article : Google Scholar : PubMed/NCBI
19	Ginhoux F and Guilliams M: Tissue-resident macrophage ontogeny and homeostasis. Immunity. 44:439–449. 2016. View Article : Google Scholar : PubMed/NCBI
20	Xu-Vanpala S, Deerhake ME, Wheaton JD, Parker ME, Juvvadi PR, MacIver N, Ciofani M and Shinohara ML: Functional heterogeneity of alveolar macrophage population based on expression of CXCL2. Sci Immunol. 5:eaba73502020. View Article : Google Scholar : PubMed/NCBI
21	Du J, Li G, Jiang L, Zhang X, Xu Z, Yan H, Zhou Z, He Q, Yang X and Luo P: Crosstalk between alveolar macrophages and alveolar epithelial cells/fibroblasts contributes to the pulmonary toxicity of gefitinib. Toxicol Lett. 338:1–9. 2021. View Article : Google Scholar : PubMed/NCBI
22	Mukaida N, Nosaka T, Nakamoto Y and Baba T: Lung macrophages: Multifunctional regulator cells for metastatic cells. Int J Mol Sci. 20:1162018. View Article : Google Scholar : PubMed/NCBI
23	Li Z, Maeda D, Yoshida M, Umakoshi M, Nanjo H, Shiraishi K, Saito M, Kohno T, Konno H, Saito H, et al: The intratumoral distribution influences the prognostic impact of CD68- and CD204-positive macrophages in non-small cell lung cancer. Lung Cancer. 123:127–135. 2018. View Article : Google Scholar : PubMed/NCBI
24	Casanova-Acebes M, Dalla E, Leader AM, LeBerichel J, Nikolic J, Morales BM, Brown M, Chang C, Troncoso L, Chen ST, et al: Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells. Nature. 595:578–584. 2021. View Article : Google Scholar : PubMed/NCBI
25	Cotechini T, Atallah A and Grossman A: Tissue-resident and recruited macrophages in primary tumor and metastatic microenvironments: Potential targets in cancer therapy. Cells. 10:9602021. View Article : Google Scholar : PubMed/NCBI
26	Strober W: Trypan blue exclusion test of cell viability. Curr Protoc Immunol. 111:A3.B.1–A3.B.3. 2015. View Article : Google Scholar : PubMed/NCBI
27	Zhao BX, Wang J, Song B, Wei H, Lv WP, Tian LM, Li M and Lv S: Establishment and biological characteristics of acquired gefitinib resistance in cell line NCI-H1975/gefinitib-resistant with epidermal growth factor receptor T790M mutation. Mol Med Rep. 11:2767–2774. 2015. View Article : Google Scholar : PubMed/NCBI
28	Li M, Zhang Q, Liu L, Liu Z, Zhou L, Wang Z, Yue S, Xiong H, Feng L and Lu S: The different clinical significance of EGFR mutations in exon 19 and 21 in non-small cell lung cancer patients of China. Neoplasma. 58:74–81. 2011. View Article : Google Scholar : PubMed/NCBI
29	Sun Xuerui WY, Jialin G and Li Mei: Difference between LCGreen PLUS and EvaGreen in detecting EGFR mutation with HRM. J Dalian Med Univ. 42:391–394. 2020.
30	R Core Team. R, . A language and environment for statistical computing. R Foundation for Statistical Computing; Vienna, Austria: ISBN 3-900051-07-0, URL. http://www.R–project.org/
31	Hakuno F and Takahashi SI: IGF1 receptor signaling pathways. J Mol Endocrinol. 61:T69–T86. 2018. View Article : Google Scholar : PubMed/NCBI
32	Ark AV, Cao J and Li X: TGF-β receptors: In and beyond TGF-beta signaling. Cell Signal. 52:112–120. 2018. View Article : Google Scholar : PubMed/NCBI
33	Rotow J and Bivona TG: Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer. 17:637–658. 2017. View Article : Google Scholar : PubMed/NCBI
34	Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
35	Batlle E and Massague J: Transforming growth factor-β signaling in immunity and cancer. Immunity. 50:924–940. 2019. View Article : Google Scholar : PubMed/NCBI
36	Caja L, Dituri F, Mancarella S, Caballero-Diaz D, Moustakas A, Giannelli G and Fabregat I: TGF-β and the tissue microenvironment: Relevance in fibrosis and cancer. Int J Mol Sci. 19:12942018. View Article : Google Scholar : PubMed/NCBI
37	Yu X, Buttgereit A, Lelios I, Utz SG, Cansever D, Becher B and Greter M: The cytokine TGF-beta promotes the development and homeostasis of alveolar macrophages. Immunity. 47:903–912. e9042017. View Article : Google Scholar : PubMed/NCBI
38	Wang H, Wang X, Li X, Fan Y, Li G, Guo C, Zhu F, Zhang L and Shi Y: CD68(+)HLA-DR(+) M1-like macrophages promote motility of HCC cells via NF-κB/FAK pathway. Cancer Lett. 345:91–99. 2014. View Article : Google Scholar : PubMed/NCBI
39	Yao Z, Fenoglio S, Gao DC, Camiolo M, Stiles B, Lindsted T, Schlederer M, Johns C, Altorki N, Mittal V, et al: TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci USA. 107:15535–15540. 2010. View Article : Google Scholar : PubMed/NCBI
40	Fukuoka M, Yoshioka K and Hohjoh H: NF-κB activation is an early event of changes in gene regulation for acquiring drug resistance in human adenocarcinoma PC-9 cells. PLoS One. 13:e02017962018. View Article : Google Scholar : PubMed/NCBI
41	Wan L, Wang Y, Tang Y, Tan Y, He F, Zhang Y, Yang K, Chen Z, Song C, Gu R, et al: Gefitinib-induced cutaneous toxicities in brown norway rats are associated with macrophage infiltration. Inflammation. 43:2137–2146. 2020. View Article : Google Scholar : PubMed/NCBI
42	Bukowski K, Kciuk M and Kontek R: Mechanisms of multidrug resistance in cancer chemotherapy. Int J Mol Sci. 21:32332020. View Article : Google Scholar : PubMed/NCBI
43	Anderson NR, Minutolo NG, Gill S and Klichinsky M: Macrophage-based approaches for cancer immunotherapy. Cancer Res. 81:1201–1208. 2021. View Article : Google Scholar : PubMed/NCBI
44	Kennedy LB and Salama AKS: A review of cancer immunotherapy toxicity. CA Cancer J Clin. 70:86–104. 2020. View Article : Google Scholar : PubMed/NCBI
45	Im JS, Herrmann AC, Bernatchez C, Haymaker C, Molldrem JJ, Hong WK and Perez-Soler R: Immune-modulation by epidermal growth factor receptor inhibitors: Implication on anti-tumor immunity in lung cancer. PLoS One. 11:e01600042016. View Article : Google Scholar : PubMed/NCBI
46	Hussaini S, Chehade R, Boldt RG, Raphael J, Blanchette P, Vareki SM and Fernandes R: Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors-A systematic review and meta-analysis. Cancer Treat Rev. 92:1021342021. View Article : Google Scholar : PubMed/NCBI